This activity was originally presented as a part of Directions in Pharmacy 2025.
Program Description
Respiratory syncytial virus (RSV) is a significant yet often underrecognized cause of severe respiratory illness in adults, particularly in older populations and those with comorbid conditions. This program will explore the epidemiology, pathophysiology, and clinical burden of RSV in adults, emphasizing the challenges in diagnosis and differentiation from other respiratory infections. The latest Advisory Committee on Immunization Practices (ACIP) guidelines, the efficacy and safety of available RSV vaccines, and best practices for vaccine implementation based on patient risk factors will be reviewed. The discussion will also highlight best practices for pharmacists to lead patient education efforts, vaccine advocacy, and addressing hesitancy to improve vaccine uptake.
Target audience: Community, ambulatory care, and health system pharmacists
Type of activity: Application
Release date: June 16, 2025
Expiration date: June 16, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore risk factors for severe respiratory syncytial virus (RSV) complications in adults and the clinical and economic burden of disease
- Explain the latest ACIP and CDC recommendations and recent efficacy and safety data on RSV vaccination in adults
- Examine strategies to enhance awareness and uptake of RSV vaccination among high-risk adults to improve patient outcomes
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here